KOSDAQChemicals250030

Jincostech

₩7,890▲ 1.15%2026-11-18 close
Market Cap
₩29.9B
Turnover
₩200M
Volume
30K
Shares out.
3.8M
PER
4.4×
PBR
—
EPS
₩1,758
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit recovery meets mask-pack concentration; plant expansion is the next test

Jincostech returned to profit in 2025 and its revenue rose for three consecutive quarters through the third quarter of 2026, but reliance on hydrogel mask packs and working-capital needs remain open questions.

  1. 1

    The operating margin rose to 10.0% in 2025 from 3.9% in 2024, and net income attributable to controlling shareholders turned to KRW 6.02 billion from a loss.

  2. 2

    Third-quarter 2026 revenue rose 40.9% year on year to KRW 21.3 billion, while operating profit fell 12.1% year on year to KRW 2.12 billion.

  3. 3

    Hydrogel products made up 89.11% of sales in the first half of 2026, and mask packs alone accounted for roughly 94%, leaving heavy concentration in one product family.

  4. 4

    The third plant, with an expected investment of KRW 8 billion, is set to begin full operation in April 2027, and the company targets a capacity increase of more than 40%.

  5. 5

    Operating cash flow was a net outflow of about KRW 0.5 billion in the first half of 2026, while receivables and inventory increased sharply over the same period.

02

Business structure

Jincostech, founded in 2010, is a cosmetics ODM and OEM company that handles hydrogel mask packs and eye patches from formulation design through mass production and quality control.

Clients set the concept and the company designs the formulation, so brand customers can launch products without building their own research or production facilities.

As of 2025, full-face hydrogel mask packs accounted for 44.0% of revenue and partial-area hydrogel patches for 42.3%, so hydrogel products together made up 86.3%. Some reports put the 2025 mask-pack share at 92.6%, and the two figures use different product classifications and should be read together.

Basic skincare sales fell from KRW 3.6 billion in 2025 to KRW 1.8 billion in the first half of 2026. Overseas sales were KRW 8.2 billion in the first half of 2026, or 26.5% of the total, centered on the United States and Southeast Asia.

The customer base is not concentrated: in the first half of 2026 the largest customer accounted for 19.1% of revenue and the top two for 29.7%. Utilization in the first half of 2026 was 101.65% for hydrogel masks, 26.82% for sheet masks and 6.41% for basic cosmetics. The company plans to pair a third plant with a wider range of functional patches and cosmeceuticals.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.1B₩2.4B15.9%
2025Q4₩10.3B-₩100M−1.4%
2026Q1₩13.5B₩1.2B8.8%
2026Q2₩17.5B₩2.3B13.0%
2026Q3₩21.3B₩2.1B9.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩17.6B-₩3.2B-₩4.7B−18.2%−79.2%460.1%
2023₩19.5B-₩2.6B-₩3.5B−13.4%−144.1%1228.8%
2024₩29.8B₩1.1B-₩41,201,3803.9%−1.7%1305.3%
2025₩48.6B₩4.8B₩6B10.0%32.0%176.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Based on DART-filed results, revenue rose from KRW 17.6 billion in 2022 to KRW 19.5 billion in 2023 (up 10.9% year on year), KRW 29.8 billion in 2024 (up 52.8%) and KRW 48.6 billion in 2025 (up 63.0%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of the 2022 to 2025 period.

Operating losses of KRW 3.19 billion in 2022 and KRW 2.61 billion in 2023 turned into operating profit of KRW 1.15 billion in 2024, and reached KRW 4.85 billion in 2025, up 321.7% year on year. The operating margin moved from -18.2% in 2022 and -13.4% in 2023 to 3.9% in 2024 and 10.0% in 2025.

The company attributes the improvement to higher sales of hydrogel mask packs and patches, better production efficiency and a lower cost ratio.

Net losses attributable to controlling shareholders narrowed from KRW 4.66 billion in 2022 and KRW 3.47 billion in 2023 to KRW 41.2 million in 2024, and the company returned to net income of KRW 6.02 billion in 2025. Net income including non-controlling interests was also KRW 6.02 billion in 2025.

The debt ratio fell from 1,228.8% in 2023 and 1,305.3% in 2024 to 176.8% in 2025, when total equity was KRW 18.8 billion and total liabilities were KRW 33.2 billion.

Operating cash flow moved from outflows of KRW 3.18 billion in 2022 and KRW 1.34 billion in 2023 to inflows of KRW 2.21 billion in 2024 and KRW 5.31 billion in 2025.

Quarterly revenue bottomed at KRW 10.3 billion in the fourth quarter of 2025, down 32.0% from the prior quarter, and then rose for three consecutive quarters to KRW 13.5 billion, KRW 17.5 billion and KRW 21.3 billion through the third quarter of 2026.

Operating profit swung from an operating loss of KRW 145 million in the fourth quarter of 2025 to KRW 1.19 billion in the first quarter of 2026 and KRW 2.27 billion in the second quarter, then fell 6.7% from the prior quarter to KRW 2.12 billion in the third quarter.

Third-quarter 2026 revenue grew 40.9% year on year while operating profit fell 12.1% year on year, so margins compressed as the top line expanded.

05

Industry analysis

The market Jincostech serves is being reported as one where hydrogel orders are growing alongside the spread of K-beauty. The company says its main production lines were effectively running at full capacity as of the first half of 2026, framing demand as ahead of supply.

Reports also point out that large cosmetics manufacturers entering the fast-growing hydrogel mask market could intensify competition. The cosmetics market has a high share of indie brands, so results can swing with the success of individual brands.

To offset this, the company is pursuing repeat orders from existing clients alongside new client inflows. On competitive positioning, the company highlights its ODM structure, which covers formulation design through mass production and quality control, and its CGMP-certified production system.

The sector classification is chemicals, but the actual business is cosmetics ODM, so direct comparisons with petrochemical-focused listed chemical companies offer limited insight. Whether the cycle has peaked will depend on utilization trends and the pace of new supply after 2027.

06

Outlook

The most specific plan the company has disclosed is a third plant. It intends to lease about 2,000 pyeong in Siheung or Ansan and add two water-soluble hydrogel production lines, with an expected investment of KRW 8 billion. Once complete, the company targets capacity more than 40% above current levels.

After trial production and commissioning, the plant is set to begin full operation in April 2027, and the company says it would add more than KRW 20 billion in revenue-equivalent capacity. Funding for the expansion is to come from the proceeds of the KOSDAQ transfer listing.

On products, the company plans to extend its range from patches to basic skincare, sunscreens and a hair-loss-relief shampoo. Overseas, it plans to widen its client base from North America to Europe, the Middle East and Southeast Asia, and to find new brand, distributor and vendor partners.

However, basic skincare revenue fell from KRW 3.6 billion in 2025 to KRW 1.8 billion in the first half of 2026, so the pace at which product diversification turns into sales still needs confirming. One press analysis says new product lines will take time to build a profit base that complements the core business.

Working-capital demands from the expansion also merit attention, with receivables at KRW 7.8 billion and inventory at KRW 7.1 billion as of the first half of 2026.

07

Valuation

PER
4.4×
PBR
—
ROE
27.2%
EPS
₩1,758
BPS
—
Dividend per share
₩0

Valuation is generally assessed on earnings. Jincostech posted net losses through 2024, so earnings-based multiples could not be compared until net income attributable to controlling shareholders turned positive in 2025.

Net income attributable to controlling shareholders over the last four quarters totals KRW 4.92 billion, and quarterly swings are large. It was KRW 310 million in the fourth quarter of 2025 and recovered to KRW 1.67 billion in the third quarter of 2026, although that quarter was down 12.9% from the prior quarter.

On the asset side, the price-to-book ratio, measured against total equity of KRW 18.8 billion at the end of 2025, is a reference point. The debt ratio fell from 1,305.3% in 2024 to 176.8% in 2025, which reflects an easing of financial burden.

Dividends contribute little to total shareholder return at present, so returns depend on share price movement. Changes in the offering float and tradable shares after listing are a supply-side variable.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Earnings turnaround visible in the numbers

After operating losses in 2022 and 2023, the company returned to operating profit in 2024 and turned net income attributable to controlling shareholders to KRW 6.02 billion in 2025. The operating margin rose from 3.9% in 2024 to 10.0% in 2025. The company links this to a higher share of hydrogel products, which carry lower cost burdens.

Capacity expansion planned against strong demand

In the first half of 2026, hydrogel mask utilization reached 101.65%, meaning production lines were effectively full. The third plant is set to begin full operation in April 2027, and the company expects it to add more than KRW 20 billion in revenue-equivalent capacity. This would expand the physical capacity to convert demand into sales.

Client diversification and rising overseas share

In the first half of 2026, the largest client accounted for 19.1% of revenue and the top two for 29.7%, so dependence on any one customer is limited. Overseas sales were KRW 8.2 billion in the same period, or 26.5% of the total. A broad client base reduces exposure to the performance of any single brand.

09

Bear factors

Heavy reliance on mask packs persists

The mask-pack share of sales was reported at 92.6% in 2025 and rose to about 94% in the first half of 2026. Diversification is underway, but the revenue mix still leans heavily on one product family.

Cash flow and working-capital strain

Operating cash flow was a net outflow of about KRW 0.5 billion in the first half of 2026, which means operating profit of about KRW 3.5 billion did not fully translate into cash. Over the same period, receivables rose from KRW 3.3 billion to KRW 7.8 billion and inventory from KRW 4.4 billion to KRW 7.1 billion. Working-capital management becomes more important alongside the expansion investment.

Rising competition and third-quarter margin pressure

In the third quarter of 2026, revenue grew year on year while operating profit declined, which lowered the margin. Commentary points out that large cosmetics producers could enter the hydrogel mask market as it grows. Revenue growth did not translate into profit growth in that quarter, so defending margins remains a challenge.

10

Risk factors

Client brand performance swings

Because the cosmetics market has many indie brands, order volumes can swing sharply depending on whether a given brand succeeds. The company is seeking to reduce this by growing repeat orders from existing clients alongside new inflows. Client conditions change with external factors, so the order trend of major clients needs continued monitoring.

Expansion execution and utilization risk

The third plant has an expected investment of KRW 8 billion and targets full operation in April 2027. If trial production or commissioning slips, or demand grows less than expected, the fixed costs of new capacity could weigh on results.

Whether the planned capacity increase of more than 40% converts into sales can only be confirmed after the plant starts operating.

Post-listing supply and demand changes

The offering comprised 852,000 shares. As the company moves from KONEX to KOSDAQ, trading patterns and investor composition may shift. Changes in offering float and tradable shares after listing can add to share-price volatility, so trading trends should be watched alongside fundamentals.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will confirm full-year revenue, operating margin, net income attributable to controlling shareholders and fourth-quarter 2026 results. The key point is whether the fourth quarter extends the third-quarter margin decline.

  2. April 2027

    The third plant begins full operation. The check is whether capacity rises by more than 40% in practice and how early-stage costs and fixed-cost burdens look.

  3. Mid-May 2027 (first-quarter report filing deadline)

    The first-quarter 2027 results will show whether operating cash flow turns positive and whether receivables and inventory stabilize in line with sales growth.

  4. Mid-August 2027 (half-year report filing deadline)

    The half-year 2027 report will show whether new product lines such as basic skincare and sunscreen grow as a share of sales and how overseas revenue, at 26.5% in the first half of 2026, changes.

12

Overall view

Jincostech moved from operating losses in 2022 and 2023 to a 10.0% operating margin and net income attributable to controlling shareholders turning positive in 2025. Revenue grew from KRW 17.6 billion in 2022 to KRW 48.6 billion in 2025 and reached KRW 31.0 billion in the first half of 2026.

However, most revenue is concentrated in hydrogel mask packs, and operating profit fell year on year in the third quarter of 2026 even as revenue grew. Operating cash flow was also a net outflow in the first half of 2026, leaving receivables and inventory growth as a burden.

On production, utilization is high, which makes April 2027, when the third plant starts full operation, a key point. Strengths include the recovery in earnings capacity and the ability to meet demand, while weaknesses include product concentration, working-capital needs and rising competition.

The next points to check are the full-year operating margin in the 2026 annual report, the working-capital trend in the first quarter of 2027, and utilization after the third plant starts.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobplanet.co.kr
  2. incruit.com
  3. app.rndcircle.io
  4. catch.co.kr
  5. jangup.com
  6. bizno.net
  7. bloter.net
  8. lab.incruit.com
  9. dealsite.co.kr
  10. etoday.co.kr
  11. bloter.net
  12. m.news.nate.com
  13. supple.kr
  14. glasswallet.com
  15. marketin.edaily.co.kr
  16. job.gg.go.kr
  17. bloter.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis